All In Biotech

Drug Trial Radar · NCT01665144

Exploring the Efficacy and Safety of Siponimod in Patients With Secondary Progressive Multiple Sclerosis (EXPAND)

A Multicenter, Randomized, Double-blind, Parallel-group, Placebo-controlled Variable Treatment Duration Study Evaluating the Efficacy and Safety of Siponimod (BAF312) in Patients With Secondary Progressive Multiple Sclerosis Followed by Extended Treatment With Open-label BAF312.

Last checked: Nov 20, 2026Latest source record: Jun 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,651 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,651

Actual

Start

Dec 20, 2012

Primary completion

Apr 29, 2016

Study completion Mar 31, 2023

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Aug 15, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluate the safety and efficacy of Siponimod (BAF312) versus placebo in a variable treatment duration in patients with secondary progressive multiple sclerosis (Core Part) followed by extended treatment with open-label BAF312 to obtain data on long-term safety, tolerability and efficacy (Extension Part).

Conditions

  • Secondary Progressive Multiple Sclerosis

Interventions

  • BAF312Drug

    0.25, 0.5, 1, and 2 mg film-coated tablets

  • PlaceboDrug

    Film-coated tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With 3-month Confirmed Disability Progression (CDP) Events as Measured by the Expanded Disability Status Scale (EDSS)Time frame: Baseline, every 3 month up to the maximum of approximately 3 years

Locations

290 sites in 31 countries. Site status is shown where the registry gives one.

  • Novartis Investigative Site

    Phoenix, Arizona

  • Novartis Investigative Site

    Berkeley, California

  • Novartis Investigative Site

    Los Angeles, California

  • Novartis Investigative Site

    Oceanside, California

  • Novartis Investigative Site

    Sacramento, California

  • Novartis Investigative Site

    Aurora, Colorado

  • Novartis Investigative Site

    Basalt, Colorado

  • Novartis Investigative Site

    Boulder, Colorado

  • Novartis Investigative Site

    Colorado Springs, Colorado

  • Novartis Investigative Site

    Englewood, Colorado

  • Novartis Investigative Site

    Fairfield, Connecticut

  • Novartis Investigative Site

    Delray Beach, Florida

  • Novartis Investigative Site

    Hollywood, Florida

  • Novartis Investigative Site

    Jacksonville, Florida

  • Novartis Investigative Site

    Maitland, Florida

  • Novartis Investigative Site

    Ormond Beach, Florida

  • Novartis Investigative Site

    Port Charlotte, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Tampa, Florida

  • Novartis Investigative Site

    Vero Beach, Florida

  • Novartis Investigative Site

    Chicago, Illinois

  • Novartis Investigative Site

    Evanston, Illinois

  • Novartis Investigative Site

    Flossmoor, Illinois

  • Novartis Investigative Site

    Lenexa, Kansas

  • Novartis Investigative Site

    Baltimore, Maryland

  • Novartis Investigative Site

    Ann Arbor, Michigan

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Detroit, Michigan

  • Novartis Investigative Site

    Plymouth, Minnesota

  • Novartis Investigative Site

    St Louis, Missouri

  • Novartis Investigative Site

    Las Vegas, Nevada

  • Novartis Investigative Site

    Lebanon, New Hampshire

  • Novartis Investigative Site

    Freehold, New Jersey

  • Novartis Investigative Site

    Albuquerque, New Mexico

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    New York, New York

  • Novartis Investigative Site

    Patchogue, New York

  • Novartis Investigative Site

    Stony Brook, New York

  • Novartis Investigative Site

    Charlotte, North Carolina

  • Novartis Investigative Site

    Akron, Ohio

Showing 40 of 290 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.